Susquehanna International Group, LLP Protagonist Therapeutics, Inc Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2025

A detailed history of Susquehanna International Group, LLP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 192,239 shares of PTGX stock, worth $8.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

192,239

Previous 69,937 174.87%

Holding current value

$8.57 Million

Previous $2.7 Million 244.42%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$35.09 - $59.76 $4.29 Million - $7.31 Million	122,302 Added 174.87%	192,239 $9.3 Million
Q4 2024 Feb 14, 2025	BUY	$38.51 - $48.43 $1.14 Million - $1.43 Million	29,580 Added 73.3%	69,937 $2.7 Million
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $10.6 Million - $14.9 Million	-315,229 Reduced 88.65%	40,357 $1.81 Million
Q2 2024 Aug 15, 2024	BUY	$24.66 - $34.8 $7 Million - $9.88 Million	283,768 Added 395.12%	355,586 $12.3 Million
Q1 2024 May 07, 2024	SELL	$21.79 - $32.15 $825,078 - $1.22 Million	-37,865 Reduced 34.52%	71,818 $2.08 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $736,753 - $1.23 Million	52,438 Added 91.6%	109,683 $2.52 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $688,567 - $976,708	41,281 Added 258.59%	57,245 $954,000
Q2 2023 Aug 11, 2023	SELL	$18.02 - $29.36 $1.95 Million - $3.17 Million	-108,120 Reduced 87.13%	15,964 $440,000
Q1 2023 May 16, 2023	BUY	$10.78 - $25.38 $615,031 - $1.45 Million	57,053 Added 85.11%	124,084 $2.85 Million
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $584,803 - $887,534	-79,457 Reduced 54.24%	67,031 $731,000
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $639,238 - $952,350	81,328 Added 124.81%	146,488 $1.24 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $101,706 - $367,641	14,406 Added 28.38%	65,160 $516,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $5.73 Million - $8.86 Million	-245,659 Reduced 82.88%	50,754 $1.2 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $511,798 - $1.08 Million	29,030 Added 10.86%	296,413 $10.1 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $3.19 Million - $12.2 Million	246,050 Added 1153.38%	267,383 $4.74 Million
Q2 2021 Aug 11, 2021	SELL	$25.57 - $44.88 $327,321 - $574,508	-12,801 Reduced 37.5%	21,333 $957,000
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $262,114 - $429,278	13,781 Added 67.71%	34,134 $884,000
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $168,869 - $229,512	9,133 Added 81.4%	20,353 $410,000
Q3 2020 Nov 16, 2020	BUY	$15.19 - $22.4 $170,431 - $251,327	11,220 New	11,220 $219,000
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $429,136 - $619,332	-47,788 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $211,770 - $448,626	32,580 Added 214.23%	47,788 $601,000
Q4 2018 Feb 14, 2019	BUY	$6.3 - $10.44 $95,810 - $158,771	15,208 New	15,208 $102,000

Others Institutions Holding PTGX

# of Institutions

293

Shares Held

60.7M

Call Options Held

1.01M

Put Options Held

555K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.19B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Protagonist Therapeutics, Inc Transaction History